Ironwood Pharmaceuticals (IRWD) EBT (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBT across 17 years of filings, most recently posting $73.7 million for Q2 2026.

• In Q2 2026, EBT rose 94.94% year-over-year to $73.7 million; the TTM figure through Jun 2026 stood at $298.5 million (up 106.14% YoY), while the FY2025 annual figure was $161.2 million, down 3.55% from the prior year.
• EBT came in at $73.7 million for Q2 2026 at Ironwood Pharmaceuticals, up from $65.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $125.9 million in Q4 2024 to a low of -$1.1 billion in Q2 2023.
• Average EBT over 5 years is -$25.3 million, with a median of $55.1 million recorded in 2022.
• Year-over-year, EBT plunged 2100.97% in 2023 and soared 291.62% in 2025.
• Over 5 years, EBT stood at $72.3 million in 2022, then plunged by 371.46% to -$196.2 million in 2023, then surged by 164.17% to $125.9 million in 2024, then dropped by 27.25% to $91.6 million in 2025, then fell by 19.49% to $73.7 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $73.7 million in Q2 2026, $65.2 million in Q1 2026, and $91.6 million in Q4 2025.